Oil Prices Rebound as Strait of Hormuz Tensions Return After Ship Attack Near Oman 
Australia Jobs Growth Strengthens Rate Hike Outlook 
China Eastern Orders 25 Airbus A330neo Jets in $9.35 Billion Deal to Boost International Expansion 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Asian Markets Rally as Micron and Qualcomm AI Outlook Lifts Global Tech Stocks 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
CDC Expands Ebola Screening Efforts at U.S. Entry Points Amid Congo and Uganda Outbreak 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
US Judge Seeks Explanation for DOJ’s Decision to Drop Gautam Adani Bribery Case 
TrumpRx Expands Discount Drug Access With 600 Generic Medications 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
RFK Jr. Spokesman Resigns Over Trump Administration’s Flavored E-Cigarette Policy 
South Korea’s KOSPI Plunges as Apple Price Hikes and OpenAI IPO Delay Shake AI Chip Stocks 
Novavax raised doubts about the feasibility of continuing its business after struggles in rolling out its coronavirus jab although it has enough money to fund operations.
The COVID-19 vaccine maker, which described the situation as "subject to significant uncertainty," also announced plans to cut spending
On Tuesday, the company reported a loss of $182 million in the fourth quarter, after posting weaker sales than expected at $357 million.
Consequently, Novavax shares plummeted 25 percent in extended trading.
Novavax is currently gearing up for a fall vaccination campaign and said it plans to focus on delivering an updated COVID-19 vaccine.
The Maryland-based Novavax was an early frontrunner in the global vaccine race but fell behind after being hit by manufacturing and regulatory delays.
The company faced delays in regulatory submissions for its jab, which was only authorized in the US in July last year.
Before that, it received authorization from the European Union, United Kingdom, Canada, and Australia.
